2018 annual financial data
Spero Therapeutics 2018 Operating margin
Direct answer
Operating margin was -1,079.32%.
Operating income was -42,806,000 USD and net income was -41,662,000 USD.
Operating cash flow was -39,625,000 USD.
Get free Spero Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3,966,000 USD
- Operating income
- -42,806,000 USD
- Net income
- -41,662,000 USD
- Operating cash flow
- -39,625,000 USD